Evidence map›Paper›PMID 26119730›Full record

ArticleCell reports2015

Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma.

Edward L LaGory, Colleen Wu, Cullen M Taniguchi, Chien-Kuang Cornelia Ding, Jen-Tsan Chi, Rie von Eyben, David A Scott, Adam D Richardson, Amato J Giaccia

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 134 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mitochondrial function meets oncology: the multifaceted role of TFAM across cancer types.Apoptosis : an international journal on programmed cell death · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Edward L LaGoryDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Colleen WuDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Cullen M TaniguchiDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Chien-Kuang Cornelia DingDuke Center for Genomic and Computational Biology, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27708, USA.
Jen-Tsan ChiDuke Center for Genomic and Computational Biology, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27708, USA.
Rie von EybenDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
David A ScottNCI-Designated Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA.
Adam D RichardsonNCI-Designated Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA.
Amato J GiacciaDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA. Electronic address: giaccia@stanford.edu.
Stanford University · USDuke Medical Center · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
TUMOR HYPOXIA--MOLECULAR STUDIES &CLINICAL EXPLOITATIONP01CA067166 · NCI · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN · 1996 to 2017
$25.5M
Genetics Training Grant-Year 26T32GM007754 · NIGMS · DUKE UNIVERSITY · PI HAASE, STEVEN B · 1985 to 2019
$8.3M
The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor GrowthR35CA197713 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2015 to 2021
$5.3M
HYPOXIA AND GENE REPRESSIONR01CA088480 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2000 to 2009
$3.4M
Gene expression programs of lactic acidosis in human cancersR01CA125618 · NCI · DUKE UNIVERSITY · PI CHI, JEN-TSAN ASHLEY · 2007 to 2016
$3.3M
Oncogenic Gene Regulatory NetworksR01CA106520 · NCI · DUKE UNIVERSITY · PI CHI, JEN-TSAN ASHLEY · 2005 to 2014
$2.9M
Postdoctoral Training in the Radiation ScincesT32CA121940 · NCI · STANFORD UNIVERSITY · PI GRAVES, EDWARD E. · 2007 to 2018
$2.1M
Hypoxia and Gene RepressionR37CA088480 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2010 to 2014
$1.6M
CTGF in Pancreatic Tumor GrowthR01CA116685 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2006 to 2010
$1.3M
Canadian Institutes of Health ResearchNCI NIH HHS 5P30CA030199NCI NIH HHS CA106520NCI NIH HHS CA116685NCI NIH HHS CA121940NCI NIH HHS CA125618NCI NIH HHS CA 67166NCI NIH HHS CA67166NCI NIH HHS CA 88480NCI NIH HHS P01 CA067166NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA088480NCI NIH HHS R01 CA106520NCI NIH HHS R01 CA116685NCI NIH HHS R01 CA125618NCI NIH HHS R35 CA197713NCI NIH HHS T32 CA121940NIGMS NIH HHS T32 GM007754
6 · The paper itself

Abstract

Long believed to be a byproduct of malignant transformation, reprogramming of cellular metabolism is now recognized as a driving force in tumorigenesis. In clear cell renal cell carcinoma (ccRCC), frequent activation of HIF signaling induces a metabolic switch that promotes tumorigenesis. Here, we demonstrate that PGC-1α, a central regulator of energy metabolism, is suppressed in VHL-deficient ccRCC by a HIF/Dec1-dependent mechanism. In VHL wild-type cells, PGC-1α suppression leads to decreased expression of the mitochondrial transcription factor Tfam and impaired mitochondrial respiration. Conversely, PGC-1α expression in VHL-deficient cells restores mitochondrial function and induces oxidative stress. ccRCC cells expressing PGC-1α exhibit impaired tumor growth and enhanced sensitivity to cytotoxic therapies. In patients, low levels of PGC-1α expression are associated with poor outcome. These studies demonstrate that suppression of PGC-1α recapitulates key metabolic phenotypes of ccRCC and highlight the potential of targeting PGC-1α expression as a therapeutic modality for the treatment of ccRCC.

Indexed as

Oxidative PhosphorylationAnimalsCarcinogenesisCarcinoma, Renal CellCell Line, TumorHumansMiceMitochondriaOxidative StressPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaTranscription FactorsTumor Suppressor ProteinsDELEC1 protein, humanPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID26119730
PMCPMC4518559
OpenAlexW1756959975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.